carbamates has been researched along with Liver Failure in 6 studies
Liver Failure: Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " A 49-year-old female developed a severe recurrent HCV genotype 1b infection 4 months after transplantation with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/mL, and a total bilirubin level of 8." | 7.78 | Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. ( Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA, 2012) |
| " A 49-year-old female developed a severe recurrent HCV genotype 1b infection 4 months after transplantation with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/mL, and a total bilirubin level of 8." | 3.78 | Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. ( Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA, 2012) |
| " JNJ-56914845 plasma AUC0-∞ was 26%, 52%, and 45% lower in subjects with mild, moderate, and severe hepatic impairment, respectively, relative to healthy subjects with no difference in half-life among the groups." | 1.42 | Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment. ( Adkison, KK; Berg, J; Dumont, E; Elko-Simms, L; Galloway, C; Gan, J; Gardner, S; Jones, LS; Marbury, T; Saunders, J; Smith, W; Stump, PJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Deshayes, E | 1 |
| Fersing, C | 1 |
| Meunier, L | 1 |
| Quenet, F | 1 |
| Guiu, B | 1 |
| Wu, SH | 1 |
| Chu, CJ | 1 |
| Huang, YH | 1 |
| Hou, MC | 1 |
| Adkison, KK | 1 |
| Gan, J | 1 |
| Elko-Simms, L | 1 |
| Gardner, S | 1 |
| Dumont, E | 1 |
| Jones, LS | 1 |
| Saunders, J | 1 |
| Marbury, T | 1 |
| Smith, W | 1 |
| Berg, J | 1 |
| Galloway, C | 1 |
| Stump, PJ | 1 |
| Ozaras, R | 1 |
| Mete, B | 1 |
| Yemisen, M | 1 |
| Balkan, II | 1 |
| Alkan, M | 1 |
| Tabak, F | 1 |
| Welzel, TM | 1 |
| Petersen, J | 1 |
| Herzer, K | 1 |
| Ferenci, P | 1 |
| Gschwantler, M | 1 |
| Wedemeyer, H | 1 |
| Berg, T | 1 |
| Spengler, U | 1 |
| Weiland, O | 1 |
| van der Valk, M | 1 |
| Rockstroh, J | 1 |
| Peck-Radosavljevic, M | 1 |
| Zhao, Y | 1 |
| Jimenez-Exposito, MJ | 1 |
| Zeuzem, S | 1 |
| Fontana, RJ | 1 |
| Hughes, EA | 1 |
| Appelman, H | 1 |
| Hindes, R | 1 |
| Dimitrova, D | 1 |
| Bifano, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C[NCT02097966] | 0 participants | Expanded Access | No longer available | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for carbamates and Liver Failure
| Article | Year |
|---|---|
Antiviral (Hepatitis C Virus) Drug-Drug Interaction Leading to Dramatic Underestimation of Liver Function With 99mTc-Mebrofenin Hepatobiliary Scintigraphy.
Topics: Adult; Amides; Aniline Compounds; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Int | 2020 |
Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation.
Topics: Acute Disease; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C; Humans; I | 2019 |
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.
Topics: Adult; Antiviral Agents; Area Under Curve; Carbamates; Female; Half-Life; Hepacivirus; Humans; Liver | 2015 |
Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, | 2015 |
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Compassionate Use Trials; Drug Monitoring | 2016 |
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
Topics: Alkaline Phosphatase; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cholestasis; Drug Therapy | 2012 |